转移性胃癌或食管癌住院患者临终前化疗与人工营养使用差异:一项全国性登记研究
法国全国性登记研究纳入2010至2013年死亡的4031例食管癌和10423例胃癌住院成人患者,评估临终前化疗与人工营养使用情况。化疗使用率从死亡前第3个月的35.9%降至最后1周的7.9%,人工营养使用率从9.6%升至16.0%。胃癌患者最后1周接受化疗的可能性高于食管癌患者(aOR=1.35,95%CI=1.17-1.56),接受人工营养的可能性较低(aOR=0.80,95%CI=0.73-0.88)。
要点
- 化疗使用率从死亡前第3个月的35.9%降至最后1周的7.9%(趋势p<0.001)。
- 人工营养使用率从死亡前第3个月的9.6%升至最后1周的16.0%。
- 最后1周化疗调整率从农村医院的1.6%到综合癌症中心的11.2%不等。
核心结论
- 在转移性食管癌或胃癌住院患者中,随着死亡临近,化疗使用减少而人工营养使用增加。
- 作者指出,临床指南明确建议在预期寿命有限的情况下限制人工营养使用,上述现象引发重要问题。
研究设计与样本
- 全国性、基于登记的研究,纳入法国2010年至2013年死亡的所有年龄≥20岁的转移性食管癌或胃癌住院成人患者。
- 主要结局为临终前数周内的化疗和人工营养使用。
主要发现
- 共纳入4031例食管癌患者和10423例胃癌患者。
- 化疗使用率从死亡前第3个月的35.9%降至最后1周的7.9%(趋势p<0.001)。
- 人工营养使用率从死亡前第3个月的9.6%升至最后1周的16.0%。
- 死亡前最后1周,胃癌患者较食管癌患者更可能接受化疗(aOR=1.35,95%CI=1.17-1.56),但较少接受人工营养(aOR=0.80,95%CI=0.73-0.88)。
- 最后1周化疗调整率从农村医院的1.6%到综合癌症中心的11.2%不等,人工营养调整概率从私立营利诊所的12.1%到康复护理机构的19.9%不等(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate the frequency and the factors associated with the use of chemotherapy and artificial nutrition near the end of life in hospitalised patients with metastatic oesophageal or gastric cancer. METHODS: Nationwide, register-based study, including all hospitalised adults (≥20 years) who died with metastatic oesophageal or gastric cancer between 2010 and 2013, in France. Chemotherapy and artificial nutrition during the final weeks of life were considered as primary outcomes. RESULTS: A total of 4031 patients with oesophageal cancer and 10,423 patients with gastric cancer were included. While the proportion of patients receiving chemotherapy decreased from 35.9% during the 3rd month before death to 7.9% in the final week (p < 0.001 for trend), the use of artificial nutrition rose from 9.6% to 16.0% of patients. During the last week before death, patients with stomach cancer were more likely to receive chemotherapy (adjusted odds ratio (aOR) = 1.35, 95% CI = 1.17-1.56) but less likely to receive artificial nutrition (aOR = 0.80, 95%CI = 0.73-0.88) than patients with cancer of the oesophagus. The adjusted rates of chemotherapy use during the last week of life varied from 1.6% in rural hospitals to 11.2% in comprehensive cancer centres, while the adjusted probability to receive artificial nutrition varied from 12.1% in private for-profit clinics up to 19.9% in rehabilitation care facilities (p < 0.001). CONCLUSIONS: Our study shows that in hospitalised patients with metastatic oesophageal or gastric cancer, the use of chemotherapy decreases while the use of artificial nutrition increases as death approaches. This raises important questions, as clinical guidelines clearly recommend to limit the use of artificial nutrition in contexts of limited life expectancy.
引用
- Kempf E, Tournigand C, Rochigneux P, et al. Discrepancies in the use of chemotherapy and artificial nutrition near the end of life for hospitalised patients with metastatic gastric or oesophageal cancer. A countrywide, register-based study. Eur J Cancer. 2017. PMID: 28458120. doi:10.1016/j.ejca.2017.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。